Denmark’s leading pharmaceutical company, Novo Nordisk (NYSE: NVO), has reached an agreement to acquire Canada-based cardiometabolic disorder specialist Inversago Pharma by the end of the year, subject to regulatory approvals and other customary conditions. The acquisition deal could reach a total value of USD 1.1 billion if all development and commercial milestones are successfully achieved.
Boosting Novo’s Obesity Pipeline with Inversago’s Innovations
Novo Nordisk’s obesity pipeline is poised to benefit significantly from Inversago’s lead candidate, INV-202. This potential first-in-class small-molecule CB1 receptor (CB1r) blocker has already successfully cleared a Phase I trial for weight loss and has entered Phase II for diabetic kidney disease (DKD). INV-202 holds therapeutic potential across a broad spectrum of cardiometabolic and fibrotic diseases, making it a valuable addition to Novo’s portfolio.
Expanding Therapeutic Reach in Diabetes, NASH, and Fibrotic Disorders
In addition to its lead candidate, Inversago’s pre-clinical pipeline includes treatments for diabetes, non-alcoholic steatohepatitis (NASH), and fibrotic disorders. This acquisition will enable Novo Nordisk to expand its reach in these critical areas, strengthening its position as a global leader in diabetes and cardiometabolic health solutions.-Fineline Info & Tech
